Author details

Full Name

A E van Leeuwen-Stok

Affiliation

Free University Hospital

ORCID

Career Start Year

1993

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37310797	Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).	Oncologist	2023
34965952	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.	Clin Cancer Res	2022
35139727	Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.	Acta Oncol	2022
32929565	Elastosis in ERÎ±-positive male breast cancer.	Virchows Arch	2021
35087363	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).	Breast Care (Basel)	2021
34312396	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.	NPJ Breast Cancer	2021
32182822	Loss of Y-Chromosome during Male Breast Carcinogenesis.	Cancers (Basel)	2020
32188473	High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.	Breast Cancer Res	2020
28922787	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).	J Natl Cancer Inst	2018
30125761	Adjuvant dose-dense doxorubicin-cyclophosphamideÂ versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).	Eur J Cancer	2018
29092024	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.	Ann Oncol	2018
29371927	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.	Oncotarget	2017
26709068	A source document and case report form for prospective documentation of breast cancer radiotherapy parameters for use in trials or studies.	Radiother Oncol	2016
26614548	Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).	Breast	2016
27315546	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.	Cancer	2016
25556355	Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).	Breast Cancer Res Treat	2015
26025767	Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.	Eur J Cancer	2015
24314824	Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.	Breast	2014
25150151	Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.	Eur J Surg Oncol	2014
24585721	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).	Ann Oncol	2014
24504445	A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.	Ann Oncol	2014
23305962	Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.	Breast	2013
8655374	Radiotoxic effect and dosimetry of 67GA in multicellular spheroids as compared to single cells of the lymphoma cell line U715.	Int J Radiat Oncol Biol Phys	1996
8761380	Effect of modulation of the transferrin receptor on gallium-67 uptake and cytotoxicity in lymphoma cell lines.	Br J Cancer	1996
7903343	Gallium 67 in the human lymphoid cell line U-715: uptake, cytotoxicity and intracellular localization.	Int J Radiat Biol	1993

1 - 25 of 25

Chiara Corti

University of Milano

Career Start Year 2017

Number of shared co-authors 0

Carmen Criscitiello

University of Milano

Career Start Year 2008

Number of shared co-authors 3

Aditya Bardia

Massachusetts General Hospital Cancer Center

Career Start Year 2004

Number of shared co-authors 3

David W Cescon

Princess Margaret Cancer Centre

Career Start Year 2003

Number of shared co-authors 3

Philippe L Bedard

Princess Margaret Cancer Centre, University Health Network

Career Start Year 2002

Number of shared co-authors 7

Peter A Fasching

Otto-Friedrich-University Bamberg

Career Start Year 2002

Number of shared co-authors 15

Philip Wong

Princess Margaret Cancer Centre, University Health Network

Career Start Year 2002

Number of shared co-authors 0

Nicola Fusco

IEO European Institute of Oncology IRCCS

Career Start Year 2002

Number of shared co-authors 2

Massimo Cristofanilli

Weill Cornell School of Medicine

Career Start Year 1998

Number of shared co-authors 4

Francesca M Buffa

University of Oxford

Career Start Year 1998

Number of shared co-authors 0

Eleni Andreopoulou

New York Presbyterian Hospital

Career Start Year 1997

Number of shared co-authors 1

Giuseppe Curigliano

University of Milan

Career Start Year 1996

Number of shared co-authors 12

Steven J Isakoff

Massachusetts General Hospital

Career Start Year 1995

Number of shared co-authors 4

Naoto T Ueno

Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.

Career Start Year 1995

Number of shared co-authors 4

Daniel Rea

Institute of Cancer and Genomic Sciences, The University of Birmingham

Career Start Year 1993

Number of shared co-authors 10

Paul N Span

Radboud University Medical Center

Career Start Year 1993

Number of shared co-authors 11

Melania Pintilie

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1993

Number of shared co-authors 1

Vera J Suman

Mayo Clinic

Career Start Year 1992

Number of shared co-authors 2

Janet A Dunn

Warwick Clinical Trials Unit, University of Warwick

Career Start Year 1991

Number of shared co-authors 13

Ramona F Swaby

Merck & Co., Inc.

Career Start Year 1991

Number of shared co-authors 0

Joan Albanell

Hospital del Mar Research Institute

Career Start Year 1990

Number of shared co-authors 7

Val??rie Laurence

Institut Curie

Career Start Year 1990

Number of shared co-authors 0

Luc Dirix

GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp

Career Start Year 1988

Number of shared co-authors 19

Alberto Zambelli

IRCCS Humanitas Research Hospital

Career Start Year 1987

Number of shared co-authors 2

Silvia C Formenti

Weill Cornell Medical College

Career Start Year 1986

Number of shared co-authors 2

Catharine M L West

University of Manchester

Career Start Year 1981

Number of shared co-authors 0

Hans-Peter Sinn

Pathologisches Institut, Universitatsklinikum Heidelberg

Career Start Year 1981

Number of shared co-authors 5

Kathleen I Pritchard

UCL Great Ormond Street Institute of Child Health, University College London

Career Start Year 1976

Number of shared co-authors 9

Gabriel N Hortobagyi

The University of Texas MD Anderson Cancer Center

Career Start Year 1976

Number of shared co-authors 11

Larry Norton

Memorial Sloan Kettering Cancer Center

Career Start Year 1976

Number of shared co-authors 7

row(s) 1 - 30 of 30

Cornelis J H van de Velde

Leiden University Medical Center: Leids Universitair Medisch Centrum.

Co-authored papers 5

Carolien H M van Deurzen

Erasmus MC Cancer Institute

Co-authored papers 5

Carolien P Schr??der

University of Groningen, University Medical Center Groningen

Co-authored papers 4

Kathryn J Ruddy

Mayo Clinic

Co-authored papers 3

John W M Martens

Erasmus Medical Center (MC) Cancer Institute

Co-authored papers 3

Caroline Seynaeve

Erasmus Medical Center

Co-authored papers 3

Barbro Linderholm

Sahlgrenska University Hospital

Co-authored papers 3

Sharon H Giordano

The University of Texas MD Anderson Cancer Center

Co-authored papers 3

Hanneke W M van Laarhoven

Cancer Center Amsterdam

Co-authored papers 3

Coralie Poncet

Co-authored papers 3

Kim Benstead

Gloucestershire Hospitals NHS Foundation Trust

Co-authored papers 2

Joanna Vermeij

Hospital Network Antwerp (ZNA)

Co-authored papers 2

Eric P Winer

Dana-Farber Cancer Institute

Co-authored papers 2

Lavinia P Middleton

The University of Texas MD Anderson Cancer Center

Co-authored papers 2

Stefan Aebi

University of Bern

Co-authored papers 2

Aleksandra Peric

Co-authored papers 2

Fatima Cardoso

Champalimaud Clinical Center/Champalimaud Foundation

Co-authored papers 2

Jane Bayani

Ontario Institute for Cancer Research

Co-authored papers 2

John M S Bartlett

University of Edinburgh

Co-authored papers 2

Larissa A Korde

Clinical Investigations Branch, National Cancer Institute

Co-authored papers 2

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Co-authored papers 2

Lissandra Dal Lago

Institut Jules Bordet

Co-authored papers 2

Isabel T Rubio

Clinica Universidad de Navarra, Cancer Center Universidad de Navarra

Co-authored papers 2

Ingrid Hedenfalk

Lund University and Skane University Hospital

Co-authored papers 2

Peggy L Porter

Fred Hutchinson Cancer Research Center